Drug intelligence / Profile preview

ATB-1606

Development stage: Preclinical
Lead developer: Amtix Bio
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules

Overview

ATB-1606 is a novel, non-steroidal small molecule drug developed by Amtix Bio for the treatment of inflammatory and immune-related diseases. It acts as a modulator of thymic stromal lymphopoietin (TSLP), specifically inhibiting the interaction between TSLP and its receptor (TSLPR), which plays a key role in Th2-mediated immune responses. The drug is positioned as an anti-inflammatory agent with potential applications in atopic dermatitis and inflammatory bowel diseases. As of June 2025, it remains in preclinical development with no reported approvals or clinical trial results[1][2][3].

Targets

TSLP (Thymic stromal lymphopoietin)

Beyond the preview

Go deeper on ATB-1606.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATB-1606.

Explore the full profile